Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease

被引：56

作者：

Jenner, P ^{[1
]}

机构：

[1] Kings Coll London, NDRC, GKT Sch Biomed Sci, London SE1 1UL, England

来源：

NEUROLOGY | 2004年 / 63卷 / 07期

关键词：

D O I：

10.1212/WNL.63.7_suppl_2.S13

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S13 / S22

页数：10

共 154 条

[1]

Agid Y., 1987, MOVEMENT DISORD, V2, P166

[2]

Alam ZI, 1997, J NEUROCHEM, V69, P1326

[3] Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra [J].

Alam, ZI ;

Jenner, A ;

Daniel, SE ;

Lees, AJ ;

Cairns, N ;

Marsden, CD ;

Jenner, P ;

Halliwell, B .

JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) :1196-1203

[4] Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra [J].

Andringa, G ;

van Oosten, RV ;

Unger, W ;

Hafmans, TGM ;

Veening, J ;

Stoof, JC ;

Cools, AR .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (08) :3033-3043

[5] The validity of the pretreated, unilaterally MPTP-treated monkey as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297 [J].

Andringa, G ;

Vermeulen, RJ ;

Drukarch, B ;

Renier, WO ;

Stoof, JC ;

Cools, AR .

BEHAVIOURAL PHARMACOLOGY, 1999, 10 (02) :163-173

[6]

Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25

[7]

Anglade P., 1995, Society for Neuroscience Abstracts, V21, P1250

[8]

Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603

[9]

Anglade Philippe, 1996, Neurology, V46, pA467

[10]

[Anonymous], 1996, Ann Neurol, V39, P29

← 1 2 3 4 5 6 7 8 9 10 →